203 related articles for article (PubMed ID: 31833715)
1. Therapeutic Potentials of Inhibition of Jumonji C Domain-containing Demethylases in Acute Myeloid Leukemia.
Koca D; Hastar N; Engür S; Kiraz Y; Ulu GT; Çekdemir D; Baran Y
Turk J Haematol; 2020 Feb; 37(1):5-12. PubMed ID: 31833715
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Apoptotic Effects of Bortezomib and Methylstat on Multiple Myeloma Cells.
Kacı FN; Kiraz Y; Çekdemir D; Baran Y
Arch Med Res; 2020 Apr; 51(3):187-193. PubMed ID: 32111493
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
4. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
[TBL] [Abstract][Full Text] [Related]
5. Small molecular modulators of JMJD1C preferentially inhibit growth of leukemia cells.
Xu X; Wang L; Hu L; Dirks WG; Zhao Y; Wei Z; Chen D; Li Z; Wang Z; Han Y; Wei L; Drexler HG; Hu Z
Int J Cancer; 2020 Jan; 146(2):400-412. PubMed ID: 31271662
[TBL] [Abstract][Full Text] [Related]
6. Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.
Shokri G; Doudi S; Fathi-Roudsari M; Kouhkan F; Sanati MH
Leuk Res; 2018 May; 68():105-111. PubMed ID: 29602065
[TBL] [Abstract][Full Text] [Related]
7. Low HOX gene expression in PML-RARα-positive leukemia results from suppressed histone demethylation.
Rejlova K; Musilova A; Kramarzova KS; Zaliova M; Fiser K; Alberich-Jorda M; Trka J; Starkova J
Epigenetics; 2018; 13(1):73-84. PubMed ID: 29224413
[TBL] [Abstract][Full Text] [Related]
8. MPT0B169, a novel tubulin inhibitor, induces apoptosis in taxol-resistant acute myeloid leukemia cells through mitochondrial dysfunction and Mcl-1 downregulation.
Wang CC; Liu HE; Lee YL; Huang YW; Chen YJ; Liou JP; Huang HM
Tumour Biol; 2016 May; 37(5):6065-72. PubMed ID: 26608370
[TBL] [Abstract][Full Text] [Related]
9. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases.
Luo X; Liu Y; Kubicek S; Myllyharju J; Tumber A; Ng S; Che KH; Podoll J; Heightman TD; Oppermann U; Schreiber SL; Wang X
J Am Chem Soc; 2011 Jun; 133(24):9451-6. PubMed ID: 21585201
[TBL] [Abstract][Full Text] [Related]
10. KDM6 and KDM4 histone lysine demethylases emerge as molecular therapeutic targets in human acute myeloid leukemia.
Boila LD; Chatterjee SS; Banerjee D; Sengupta A
Exp Hematol; 2018 Feb; 58():44-51.e7. PubMed ID: 29111428
[TBL] [Abstract][Full Text] [Related]
11. Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells.
Agger K; Miyagi S; Pedersen MT; Kooistra SM; Johansen JV; Helin K
Genes Dev; 2016 Jun; 30(11):1278-88. PubMed ID: 27257215
[TBL] [Abstract][Full Text] [Related]
12. Notopterol-induced apoptosis and differentiation in human acute myeloid leukemia HL-60 cells.
Huang Q; Wang L; Ran Q; Wang J; Wang C; He H; Li L; Qi H
Drug Des Devel Ther; 2019; 13():1927-1940. PubMed ID: 31239643
[No Abstract] [Full Text] [Related]
13. Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia.
van Dijk AD; Hoff FW; Qiu YH; Chandra J; Jabbour E; de Bont ESJM; Horton TM; Kornblau SM
Clin Epigenetics; 2021 Jan; 13(1):21. PubMed ID: 33509276
[TBL] [Abstract][Full Text] [Related]
14. A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.
Li Y; Chen K; Zhou Y; Xiao Y; Deng M; Jiang Z; Ye W; Wang X; Wei X; Li J; Liang J; Zheng Z; Yao Y; Wang W; Li P; Xu B
Curr Cancer Drug Targets; 2015; 15(6):493-503. PubMed ID: 26282548
[TBL] [Abstract][Full Text] [Related]
15. KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition.
Boila LD; Ghosh S; Bandyopadhyay SK; Jin L; Murison A; Zeng AGX; Shaikh W; Bhowmik S; Muddineni SSNA; Biswas M; Sinha S; Chatterjee SS; Mbong N; Gan OI; Bose A; Chakraborty S; Arruda A; Kennedy JA; Mitchell A; Lechman ER; Banerjee D; Milyavsky M; Minden MD; Dick JE; Sengupta A
Leukemia; 2023 Apr; 37(4):751-764. PubMed ID: 36720973
[TBL] [Abstract][Full Text] [Related]
16. Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors.
Heo SK; Noh EK; Gwon GD; Kim JY; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
Eur J Pharmacol; 2016 Oct; 789():280-290. PubMed ID: 27477352
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide modifies global histone methylation by inhibiting Jumonji C domain-containing demethylases.
Hickok JR; Vasudevan D; Antholine WE; Thomas DD
J Biol Chem; 2013 May; 288(22):16004-15. PubMed ID: 23546878
[TBL] [Abstract][Full Text] [Related]
19. LukS-PV induces mitochondrial-mediated apoptosis and G0/G1 cell cycle arrest in human acute myeloid leukemia THP-1 cells.
Bu S; Xie Q; Chang W; Huo X; Chen F; Ma X
Int J Biochem Cell Biol; 2013 Aug; 45(8):1531-7. PubMed ID: 23702031
[TBL] [Abstract][Full Text] [Related]
20. [The effects of JARID1B siRNA on proliferation and apoptosis in HL-60 cell].
Ma XD; Han HD; Huang YQ; Zou Y
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):392-6. PubMed ID: 22781799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
